# Beam’s base editing therapy for sickle cell hits goal in pivotal trial

Source: [BioPharma Dive - Latest News](https://www.biopharmadive.com/news/beam-sickle-cell-base-editing-risto-cel-results/874242/) · 2026-11-10 · Medicine
Page: https://themorning.science/story/beam-s-base-editing-therapy-for-sickle-cell-hits-goal-in-pivotal-trial-2e8a5a1a330bfd35
Kind: research · Impact: medium

## In brief

- Beam's base editing therapy for sickle cell disease met its goal in a pivotal trial.
- Beam may submit a first-of-its-kind FDA application as soon as the end of the year.

## Why it matters

A pivotal trial meeting its primary goal is a key step for a gene-editing treatment for sickle cell disease, and the planned FDA filing would be the next regulatory step toward patient access.

## Timeline

- 2026-11-10: Pivotal trial reported to hit its goal

## Coverage

- [Beam’s base editing therapy for sickle cell hits goal in pivotal trial](https://www.biopharmadive.com/news/beam-sickle-cell-base-editing-risto-cel-results/874242/) — BioPharma Dive - Latest News, 2026-11-10

Tags: sickle cell disease, base editing, gene editing, clinical trial, gene therapy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science